<DOC>
	<DOCNO>NCT01676727</DOCNO>
	<brief_summary>This study intend collect data regard clinical utility , safety performance Medtronic CoreValve速 System Transcatheter Aortic Valve Implantation ( TAVI ) patient severe symptomatic aortic valve stenosis treatment via direct aortic access ( DA ) select . As part study analysis , resource utilization together Quality Life questionnaires data provide important input cost effectiveness analysis .</brief_summary>
	<brief_title>ADVANCE Direct Aortic</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<criteria>1 . Severe symptomatic aortic valve stenosis require treatment 2 . Acceptable candidate elective treatment Medtronic CoreValve速 System accord recent version Medtronic CoreValve速 Instructions For Use 3 . 21 year age old 4 . Patient willing able comply protocolspecified followup evaluation 5 . The patient legal representative inform nature study consent participate , authorize collection release his/her medical information sign consent form ( `` Patient Informed Consent Form '' ) 6 . Patient receive CoreValve速 device via direct aortic approach TAVI 1 . Known hypersensitivity contraindication aspirin , heparin , ticlopidine , clopidogrel , nitinol , sensitivity contrast medium adequately premedicated 2 . Sepsis , include active endocarditis 3 . Recent myocardial infarction ( &lt; 30 day ) 4 . Left ventricular atrial thrombus echocardiography 5 . Uncontrolled atrial fibrillation 6 . Mitral tricuspid valvular insufficiency ( &gt; grade II ) 7 . Previous aortic valve replacement ( mechanical valve stented bioprosthetic valve ) 8 . Evolutive recent ( within 6 month implant procedure ) cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) 9 . Patients : 1 . Vascular condition make insertion endovascular access aortic valve impossible , 2 . Symptomatic carotid vertebral arterial narrowing ( &gt; 70 % ) disease , 3 . Thoracic aortic aneurysm path delivery system 10 . Bleeding diathesis coagulopathy 11 . Patient refuse blood transfusion 12 . Estimated life expectancy le 12 month unless TAVI perform 13 . Creatine clearance &lt; 20 mL/min 14 . Active gastritis peptic ulcer disease 15 . Pregnancy intent become pregnant study follow 16 . Patient participate another trial may influence result study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Transcatheter Aortic valve Implantation</keyword>
	<keyword>Heart Valve Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
</DOC>